spacer
home > epc > autumn 2003 > eea - an overview of requirements impacting industry
PUBLICATIONS
European Pharmaceutical Contractor

EEA - An Overview of Requirements Impacting Industry

Pharmacovigilance requirements in the EU are laid down in a variety of different documents, applicable according to the status and route of authorisation (such as pre- or post-approval, centrally or nationally approved). As it can be difficult for experienced personnel in this field, yet alone a newcomer, to digest these overlapping and detailed requirements, this article provides an overview of the reporting requirements applicable to the Marketing Authorisation Holder (MAH); gives sources for further information; and reviews possible changes arising as part of the current legislative review and as the EU moves towards enlargement.

The Basic Framework

Pharmacovigilance requirements in the EU are laid down in EU Regulations (540/95 (1) and 2309/93 (2), EU Directives 65/65 (3), 75/319 (4), 2000/38 (5) and 2001/83 (6)) and EU Guidelines (for example Notice to Marketing Authorisation Holders: Volume 9 - Pharmacovigilance Guidelines (7). There are also several policy papers relating to more specific functions, for example the concept paper on monitoring compliance (CPMP (Committee for Proprietary Medicinal Products) /PhVWP (Pharmacovigilance Working Party)/1618/01 (8)) and the EMEA (European Medicines Evaluation Agency) policy paper on electronic transmission (EMEA/H/5255/01 (9)). In addition, the EU Clinical Trials Directive (2001/20/EC (10)) lays down the basis for reporting from the clinical study environment, with relevant guidances currently being finalised.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Margaret Walters, Director of Pharmacovigilance at Merck Sharp & Dohme

Margaret Walters is currently Director of the European Office of Pharmacovigilance for Merck Sharp & Dohme Ltd. She has more than 16 years' experience in many areas of pharmacovigilance along with a further 10 years in basic research at Wellcome. Margaret is a member of the EFPIA Pharmacovigilance Ad Hoc group, co-chairs the PhRMA (EU) Pharmacovigilance team, is active in the EMEA/EFPIA Joint Working Party on Electronic Submissions and was part of the original (pre-ICH) MCA MedDRA Working Party.

She is also the author of several papers and her academic links include acting as External Adviser to the Postgraduate Diploma in Pharmacovigilance at the University of Hertfordshire.

spacer
Margaret Walters
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

RSSL introduces same-day mycoplasma testing service in UK

RSSL

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement